Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1391 ARTÍCULOS , VIENDO DEL 511 AL 525

[Judgment capacity from the legal viewpoint - especially the evaluation by a notary public]

Wolf S, Nuspliger I.

Ther Umsch. 2015 Apr;72(4):247-53. doi: 10.1024/0040-5930/a000672.

[Behavioral and psychological symptoms of dementia (BPSD): how to proceed]

Savaskan E.

Ther Umsch. 2015 Apr;72(4):255-60. doi: 10.1024/0040-5930/a000673.

[Possibilities of modern imaging technologies in early diagnosis of Alzheimer disease]

Unschuld PG.

Ther Umsch. 2015 Apr;72(4):261-9. doi: 10.1024/0040-5930/a000674.

[(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease

Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Tago T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y.

Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1052-61. doi: 10.1007/s00259-015-3035-4. Epub 2015 Mar 20.

Tailored nutritional guidance for home-dwelling AD families: the Feasibility of and Elements Promoting Positive Changes in Diet (NuAD-Trial)

Puranen TM, Pitkala KH, Suominen MH.

J Nutr Health Aging. 2015 Apr;19(4):454-9. doi: 10.1007/s12603-014-0567-4.

Mouse brain magnetic resonance microscopy: Applications in Alzheimer disease

Lin L, Fu Z, Xu X, Wu S.

Microsc Res Tech. 2015 May;78(5):416-24. doi: 10.1002/jemt.22489. Epub 2015 Mar 21.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ; Florbetaben Phase 3 Study Group.

Alzheimers Dement. 2015 Aug;11(8):964-74. doi: 10.1016/j.jalz.2015.02.004. Epub 2015 Mar 28.

Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, β-amyloid toxicity, and astrocyte function

Hertz L, Chen Y, Waagepetersen HS.

J Neurochem. 2015 Jul;134(1):7-20. doi: 10.1111/jnc.13107. Epub 2015 Apr 23.

View of excellent ROAD from the CAR

Lahiri DK.

Curr Alzheimer Res. 2015;12(2):96-9. doi: 10.2174/156720501202150224091751.

Latent change score modeling as a method for analyzing the antidepressant effect of a psychosocial intervention in Alzheimer's disease

Werheid K, Köhncke Y, Ziegler M, Kurz A.

Psychother Psychosom. 2015;84(3):159-66. doi: 10.1159/000376583. Epub 2015 Mar 28.

Determinants of societal costs in Alzheimer's disease: GERAS study baseline results

Dodel R, Belger M, Reed C, Wimo A, Jones RW, Happich M, Argimon JM, Bruno G, Vellas B, Haro JM.

Alzheimers Dement. 2015 Aug;11(8):933-45. doi: 10.1016/j.jalz.2015.02.005. Epub 2015 Apr 4.

Rivastigmine for Alzheimer's disease

Birks JS, Grimley Evans J.

Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. doi: 10.1002/14651858.CD001191.pub3.

Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis

Matsunaga S, Kishi T, Iwata N.

PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. eCollection 2015.

Novel PET/SPECT probes for imaging of tau in Alzheimer's disease

Watanabe H, Ono M, Saji H.

ScientificWorldJournal. 2015;2015:124192. doi: 10.1155/2015/124192. Epub 2015 Mar 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias